AAAAAA

   
Results: 1-10 |
Results: 10
MERCK-SPONSORED SIMVASTATIN (ZOCOR) COMPLIANCE PROGRAM FOR PATIENTS USING WAL-MART PHARMACY - OF BENEFIT TO WHOM
Authors: HIRSCH RL
Citation: Rl. Hirsch, MERCK-SPONSORED SIMVASTATIN (ZOCOR) COMPLIANCE PROGRAM FOR PATIENTS USING WAL-MART PHARMACY - OF BENEFIT TO WHOM, JAMA, the journal of the American Medical Association, 279(23), 1998, pp. 1875-1876
UNTITLED
Authors: HIRSCH RL
Citation: Rl. Hirsch, UNTITLED, American journal of managed care, 3(3), 1997, pp. 504-504
FUSION-RESEARCH WITH A FUTURE
Authors: HIRSCH RL KULCINSKI G SHANNY R
Citation: Rl. Hirsch et al., FUSION-RESEARCH WITH A FUTURE, Issues in science and technology, 13(4), 1997, pp. 60-64
SAFETY AND EFFICACY OF THYMOPENTIN IN ZIDOVUDINE (AZT)-TREATED ASYMPTOMATIC HIV-INFECTED SUBJECTS WITH 200-500 CD4 CELL MM(3) - A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (VOL 8, PG 279, 1995)/
Authors: GOLDSTEIN G CONANT MA BEALL G GROSSMAN HA GALPIN JE BLICK G CALABRESE LH HIRSCH RL FISHER A STAMPONE P MEYERSON LA
Citation: G. Goldstein et al., SAFETY AND EFFICACY OF THYMOPENTIN IN ZIDOVUDINE (AZT)-TREATED ASYMPTOMATIC HIV-INFECTED SUBJECTS WITH 200-500 CD4 CELL MM(3) - A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (VOL 8, PG 279, 1995)/, Journal of acquired immune deficiency syndromes and human retrovirology, 11(3), 1996, pp. 315-315
THE PROGNOSTIC-SIGNIFICANCE OF SERUM VIRAL LOAD, CODON-215 REVERSE-TRANSCRIPTASE MUTATION AND CD4-CELLS ON PROGRESSION OF HIV DISEASE IN A DOUBLE-BLIND-STUDY OF THYMOPENTIN( T)
Authors: MERIGAN TC HIRSCH RL FISHER AC MEYERSON LA GOLDSTEIN G WINTERS MA
Citation: Tc. Merigan et al., THE PROGNOSTIC-SIGNIFICANCE OF SERUM VIRAL LOAD, CODON-215 REVERSE-TRANSCRIPTASE MUTATION AND CD4-CELLS ON PROGRESSION OF HIV DISEASE IN A DOUBLE-BLIND-STUDY OF THYMOPENTIN( T), AIDS, 10(2), 1996, pp. 159-165
LABORATORY TESTING IN PRIMARY-CARE
Authors: HIRSCH RL
Citation: Rl. Hirsch, LABORATORY TESTING IN PRIMARY-CARE, JAMA, the journal of the American Medical Association, 276(3), 1996, pp. 197-197
SAFETY AND EFFICACY OF THYMOPENTIN IN ZIDOVUDINE (AZT)-TREATED ASYMPTOMATIC HIV-INFECTED SUBJECTS WITH 200-500 CD4 CELLS MM3 - A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL/
Authors: GOLDSTEIN G CONANT MA BEALL G GROSSMAN HA GALPIN JE BLICK G CALABRESE LH HIRSCH RL FISHER A STAMPONE P MEYERSON LA
Citation: G. Goldstein et al., SAFETY AND EFFICACY OF THYMOPENTIN IN ZIDOVUDINE (AZT)-TREATED ASYMPTOMATIC HIV-INFECTED SUBJECTS WITH 200-500 CD4 CELLS MM3 - A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL/, Journal of acquired immune deficiency syndromes and human retrovirology, 8(3), 1995, pp. 279-288
CATHETER-RELATED VENOUS THROMBOSIS
Authors: HIRSCH RL
Citation: Rl. Hirsch, CATHETER-RELATED VENOUS THROMBOSIS, The American journal of medicine, 98(1), 1995, pp. 99-99
INTERNATIONAL NORMALIZED RATIO AND PROTHROMBIN TIME
Authors: HIRSCH RL
Citation: Rl. Hirsch, INTERNATIONAL NORMALIZED RATIO AND PROTHROMBIN TIME, Mayo Clinic proceedings, 68(11), 1993, pp. 1124-1124
REPORT OF THE 1992 EPRI FUSION PANEL
Authors: HIRSCH RL CULLER F HINGORANI NG TAYLOR JJ SCHNEIDER TR SPENCER DF
Citation: Rl. Hirsch et al., REPORT OF THE 1992 EPRI FUSION PANEL, Journal of fusion energy, 11(3-4), 1992, pp. 209-211
Risultati: 1-10 |